OncoMark is a pioneering company in the field of cancer diagnostics, specifically focusing on early-stage breast cancer. The company has developed a cutting-edge gene expression profiling test called OncoMasTR, which helps predict the prognosis of early-stage breast cancer. This test is designed to aid doctors in making more informed treatment decisions, ultimately improving the quality of life for cancer patients.

OncoMark primarily serves healthcare providers, including hospitals, clinics, and research institutions, who are involved in cancer diagnosis and treatment. The company operates in the global healthcare market, with a particular focus on regions such as Europe and the Middle East. OncoMark has achieved significant milestones, including the CE mark of conformity to the European In Vitro Diagnostic Directive, which is a certification that ensures the product meets EU safety and performance standards.

The business model of OncoMark revolves around the development and commercialization of diagnostic tests. They generate revenue by selling their OncoMasTR test to healthcare providers and through partnerships with research institutions. Additionally, OncoMark participates in various medical conferences and exhibitions, such as the Arab Health Exhibition and Congress and the European Society of Medical Oncology Congress, to showcase their products and expand their market reach.

OncoMark's leadership team includes CEO Mr. Des, Business Development Manager Mr. Fergus Fleming, and Chief Medical Officer Professor John Crown. The company has also been recognized for its scientific contributions, with founder and Chief Scientific Officer Professor William Gallagher receiving the prestigious Science Foundation Ireland Entrepreneurship Award.

In summary, OncoMark is dedicated to improving cancer diagnostics through innovative tests like OncoMasTR, serving healthcare providers globally, and continuously advancing their technology to enhance patient outcomes.

Keywords: cancer diagnostics, breast cancer, gene expression profiling, OncoMasTR, healthcare providers, CE mark, treatment decisions, medical conferences, global market, innovative tests.